Is Globus Medical, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Globus Medical, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued, particularly when considering its P/E ratio of 36, which is significantly higher than the peer average of 18.37 for similar companies. Additionally, the EV to EBITDA ratio stands at 13.54, while the industry average is much lower, suggesting that the company is trading at a premium compared to its peers.
In comparison to notable peers, Masimo Corp. has a P/E ratio of 179.74, while Lantheus Holdings, Inc. is more attractively valued at 10.13. The stock has underperformed against the S&P 500, with a year-to-date return of -26.99% compared to the index's 16.30%, reinforcing the notion that the stock may be overvalued at its current price of 60.39.